Loading clinical trials...
Loading clinical trials...
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07366086 · Osteogenesis Imperfecta
NCT07062588 · Osteogenesis Imperfecta (OI)
NCT07412782 · Osteogenesis Imperfecta, Osteoporosis, and more
NCT04152551 · Osteogenesis Imperfecta
NCT05317637 · Osteogenesis Imperfecta
UCLA - Division of Pediatric Nephrology
Los Angeles, California
Alfred I. DuPont Hospital for Children
Wilmington, Delaware
Intermountain Orthopedics
Boise, Idaho
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions